2024 HCPCS Code C9081

Idecabtagene vicleucel, up to 460 million autologous anti-bcma car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose

Notice	HCPCS C9081 terminated on December 31, 2021.
Short Description	Idecabtagene car pos t
HCPCS Coverage Code	D - Special coverage instructions apply
HCPCS Action Code	N - No maintenance for this code
HCPCS Action Effective Date	January 01, 2022
HCPCS Code Added Date	October 01, 2021
HCPCS Pricing Indicator Code	53 - Statute
HCPCS Multiple Pricing Indicator Code	A - Not applicable as HCPCS priced under one methodology
HCPCS Coverage Issues Manual Reference Section Number
HCPCS Type Of Service Code	9 - Other medical items or services
HCPCS Anesthesia Base Unit Quantity	0